A pharmaceutical company paying $50 million to have lawsuits dropped while maintaining that its product was never harmful has a subtle significance. After confirming a settlement agreement to settle more than 200 lawsuits related to its HPV vaccine, Gardasil, Merck & Co. is essentially in this position. According to the business, the sum is “not material” to its financial situation. In a technical sense, that is true; in 2023 alone, Gardasil made $8.9 billion in sales. However, this was never really about money.
Introduced in 2006, Gardasil was eventually approved in about 150 countries and marketed as a true medical breakthrough. It guards against human papillomavirus infections, which are strongly associated with cervical cancer. Globally, more than 900 million doses have been given out. Questioning its safety felt like fringe thinking for a long time. However, hundreds of families started suing, alleging that the vaccine caused severe autoimmune diseases, including seizures, premature ovarian insufficiency, and postural orthostatic tachycardia syndrome, which in some cases were fatal.
Among the cases, one was particularly noteworthy. California resident Jennifer Robi claimed that a Gardasil injection she had as a teenager caused a heart condition that required a wheelchair. Her lawsuit was expected to be the first Gardasil case to go to a jury and was scheduled for trial in Los Angeles state court next month. That possibility might have influenced Merck’s choice. Even a costly settlement usually feels safer than an unpredictable jury.
Since August 2022, all federal Gardasil cases have been consolidated under U.S. District Judge Kenneth D. Bell in the Western District of North Carolina. Bellwether trials, or test cases intended to demonstrate the strength of each side’s evidence, were the goal of the litigation. But a courtroom was never involved in that process. Early in 2025, Judge Bell decided that many of the main claims—especially those pertaining to POTS and POI injuries—were preempted by federal law because they went against the FDA’s vaccine labeling regulations. The plaintiffs filed an appeal. The motion was denied by the appeals court. Ironically, the current settlement agreement includes those cases that were dismissed.
Merck refuses to acknowledge any responsibility. Legally speaking, that is standard language in mass-tort settlements. However well-crafted the press release may be, there’s a feeling that settling conveys a message of its own. The settlement, according to the company, is “considerably less” than pursuing every case. That’s most likely accurate. Additionally, it is a calculation rather than a confirmation.
Another level of complexity is added by the timing. Robi’s case was prepared by Health and Human Services Secretary Robert F. Kennedy Jr., a longtime opponent of vaccines who was appointed by President Trump to head the country’s leading health agency. Kennedy waived his right to referral fees on Gardasil lawsuits that were successful. His role in this narrative, initially as a plaintiffs’ lawyer and currently as a cabinet official in charge of public health, is genuinely peculiar and worth pausing to consider.
For almost twenty years, mainstream medicine has defended Gardasil’s safety record, and the scientific literature largely agrees. Merck reiterated their belief in the effectiveness of the vaccine in their own statement. That remains unchanged by the settlement. However, it comes at a precarious time for vaccine producers, when public confidence is being put to the test in novel and unpredictable ways. Whether the Gardasil settlement will calm the larger controversy or just fuel it is still up in the air.
